Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Sc... - PubMed - NCBI

Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Sc... - PubMed - NCBI

Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4162-3. [Epub ahead of print]

Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.

Roberts MC1, Miller DP2, Shak S2, Petkov VI3.

Author information

Abstract

PURPOSE:

The Oncotype DX® Breast Recurrence Score™ (RS) assay is validated to predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients with lymph node-positive (LN+), hormone receptor-positive (HR+), HER2-negative BC. We assessed 5-year BC-specific survival (BCSS) in LN+ patients with RS results in SEER databases.

METHODS:

In this population-based study, BC cases in SEER registries (diagnosed 2004-2013) were linked to RS results from assays performed by Genomic Health (2004-2014). The primary analysis included only patients (diagnosed 2004-2012) with LN+ (including micrometastases), HR+ (per SEER), and HER2-negative (per RT-PCR) primary invasive BC (N = 6768). BCSS, assessed by RS category and number of positive lymph nodes, was calculated using the actuarial method.

RESULTS:

The proportion of patients with RS results and LN+ disease (N = 8782) increased over time between 2004 and 2013, and decreased with increasing lymph node involvement from micrometastases to ≥4 lymph nodes. Five-year BCSS outcomes for those with RS < 18 ranged from 98.9% (95% CI 97.4-99.6) for those with micrometastases to 92.8% (95% CI 73.4-98.2) for those with ≥4 lymph nodes. Similar patterns were found for patients with RS 18-30 and RS ≥ 31. RS group was strongly predictive of BCSS among patients with micrometastases or up to three positive lymph nodes (p < 0.001).

CONCLUSIONS:

Overall, 5-year BCSS is excellent for patients with RS < 18 and micrometastases, one or two positive lymph nodes, and worsens with additionally involved lymph nodes. Further analyses should account for treatment variables, and longitudinal updates will be important to better characterize utilization of Oncotype DX testing and long-term survival outcomes.

KEYWORDS:

Breast cancer; Disease-specific survival; Lymph node-positive; Oncotype DX; Recurrence Score; SEER

PMID:

 

28243896

 

DOI:

 

10.1007/s10549-017-4162-3

[PubMed - as supplied by publisher]

Specific PHGKB|Cancer|PHGKB

Breast Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Mar 03, 2017

---

• [Genetic Counseling of HBOC and Japanese Organization of HBOC].  
  Fukushima Yoshimitsu et al. Gan to kagaku ryoho. Cancer & chemotherapy 2017 Feb 44(2) 107-110
• Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.  
  Roberts Megan C et al. Breast cancer research and treatment 2017 Feb
• Can an educational application increase risk perception accuracy amongst patients attending a high-risk breast cancer clinic?  
  Keohane D et al. Breast (Edinburgh, Scotland) 2017 Feb 32192-198
• Oncologist and organizational factors associated with variation in breast cancer multigene testing.  
  Lieu Tracy A et al. Breast cancer research and treatment 2017 Feb
• Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.  
  Darooei Mina et al. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017 Feb 39(2) 1010428317694303
• Retrospective review of genomic testing in breast cancer: Does it improve outcome? 
  Gastelum Grady M et al. Breast cancer research and treatment 2017 Feb
• Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic.  
  Lim Geok-Hoon et al. Gland surgery 2017 Feb 6(1) 35-42
• Gene profiling should be offered to some patients with breast cancer, says NICE.  
  Wise Jacqui et al. BMJ (Clinical research ed.) 2016 Jun 353i3391
• Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.  
  Rapiti Elisabetta et al. Cancer medicine 2017 Feb
• Quality of life among patients after bilateral prophylactic mastectomy: a systematic review of patient-reported outcomes.  
  Razdan Shantanu N et al. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2016 25(6) 1409-21